Current position

Fisher Asset Management, LLC’s Biocryst Pharmaceuticals Inc (BCRX) position

Reported position history, portfolio importance and verified filing changes from public SEC disclosures.

Fisher Asset Management, LLCVerified through Q2 2026
Relationship snapshot

At a glance

The full verified relationship, including prior ownership episodes and exits where supported.

First reportedQ3 2021Earliest verified positive filing snapshot
Latest statusCurrent positionBased on the latest supported relationship state
Peak shares5.22MHighest verified quarter-end share count
Quarters reported20Verified quarters with shares above zero
What happened?

Fisher Asset Management, LLC first reported Biocryst Pharmaceuticals Inc in Q3 2021. The reported position was increased and reduced across later filings. Fisher Asset Management, LLC currently reports 2.60M shares. The latest verified filing showed: Sold 4.7% of the position.

Verified SEC history

Position over time

See the same verified relationship through reported shares, portfolio weight or reported value.

Metric

Gaps indicate periods that cannot be safely connected or where a verified corporate action changes the raw share scale. Stock price, when available, is market context and not a transaction price.

Key filing events

What changed

Latest filing plus the most meaningful reported changes. Unchanged quarters are collapsed by default.

Q2 2026
Sold 4.7% of the position−129.23K shares · 2.60M shares remained
Filing context

Quarter-end price $10.00

Q1 2026
Bought 10.8% more+265.69K shares · 2.73M shares reported after the change
Filing context

Quarter-end price $9.52

Q4 2025
Sold 6.3% of the position−165.13K shares · 2.47M shares remained
Filing context

Quarter-end price $7.80

Q3 2025
Sold 5.4% of the position−149.79K shares · 2.63M shares remained
Filing context

Quarter-end price $7.59

Q2 2025
Sold 8.8% of the position−269.65K shares · 2.78M shares remained
Filing context

Quarter-end price $8.96

Q1 2025
Sold 4.1% of the position−130.48K shares · 3.05M shares remained
Filing context

Quarter-end price $7.50

Portfolio importance

How important is Biocryst Pharmaceuticals Inc in Fisher Asset Management, LLC’s reported portfolio?

Relative importance is measured only within the verified primary non-option reported portfolio for each quarter.

Current portfolio weight0.0%Q2 2026
Current rank#315of 1037 reported positions
Peak portfolio weight0.0%Q3 2022
Best historical rank#213Q2 2022
SEC evidence & methodology

SEC filing evidence

Market context and filing-derived values are kept separate from actual transaction prices, which 13F filings do not disclose.

Latest verified stock price$8.572026-09-23

Market context only; not an investor transaction price.

Latest filing quarter-end price$10.00Q2 2026

Derived from validated reported value and shares where supported.

Latest verified investor filingQ2 2026 · filed 2026-08-04
Open SEC filing ↗

Coverage is bounded to the institution’s top reported positions and material events rather than every security in each Form 13F. The filing reflects reportable U.S.-listed holdings, not Fisher Investments’ complete global portfolio, client mandates, short positions, exact trade dates or execution prices. Options are reported separately.